Marc J. Braunstein, MD, PhD, discusses the greatest challenge that still exists in the treatment paradigm of multiple myeloma.
Marc J. Braunstein, MD, PhD, clinical assistant professor, Department of Medicine, co-director, Autologous Stem Cell Transplant Program, NYU Winthrop Hospital, NYU Langone Health, discusses the greatest challenge that still exists in the treatment paradigm of multiple myeloma.
The remaining challenge in multiple myeloma is that patients are still not being cured, says Braunstein. Physicians are now using multimodal approaches to treat patients with multiple myeloma and are even using monoclonal antibodies in the frontline setting similar to colleagues treating lymphomas, but the majority of patients are not cured.
There are various explanations for this, but the most prevailing explanation is that there is a myeloma stem cell that investigators are not targeting, says Braunstein. When patients are diagnosed with myeloma initially, there is a predominant clone, as well as multiple slightly different clones of the plasma cells that could be resistant to treatment and persist.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More